Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
Nautilus Biotechnology logo — Delivering on the Promise of the Human Proteome

Nautilus Biotechnology

Delivering on the Promise of the Human Proteome

Founded 2016 United States San Carlos, United States 148 employees Post-IPO Equity Total: $303.20M Biotechnology, Health Care +2

General Information

Company Name Nautilus Biotechnology
Founded Year 2016
Location United States San Carlos, United States
Employees 148
Industries Biotechnology, Health Care, Life Sciences +1
Funding Stage Post-IPO Equity
Business Model Platform, B2B, SaaS
Revenue Model Subscription, Usage Based, Product Sales
Social

BounceWatch is an independent company data service, not affiliated with Nautilus Biotechnology. To contact Nautilus Biotechnology, visit nautilus.bio.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Nautilus Biotechnology compare?

A PDF of Nautilus Biotechnology and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Nautilus Biotechnology soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

Recorded by Bounce Watch from public sources. Every entry below carries the date we observed it, and when we have not looked recently the page says so rather than leaving silence to imply nothing happened.

Grant Received Oct 27, 2026

Nautilus Biotechnology is set to receive up to $6 million from the ARPA-H-Funded SEEDS Consortium.

Nautilus Biotechnology a competitor of yours? Have our desk watch it

About Nautilus Biotechnology

Nautilus Biotechnology, founded in 2016, aims to deliver on "Delivering on the Promise of the Human Proteome," promising a breakthrough in proteomics that could transform therapeutic development, enhance medical diagnostics, and make personalized medicine viable.

The company is well-placed within the biotechnology, health care, life sciences, and pharmaceutical industries. Their headquarters is in the United States. With a multidisciplinary team spanning protein chemistry, molecular biology, and software engineering, Nautilus is leveraging collective expertise to tackle previously insurmountable challenges in their field.

In terms of funding, they secured a significant $200.00M post-IPO equity investment on June 10, 2021, involving top-tier investors including Madrona, Casdin Capital, RA Capital Management, and Andreessen Horowitz/a16z among others. These investments underscore the confidence placed in Nautilus's innovative approach to revolutionizing drug development and health management.

Business keywords: Proteomics, Therapeutic Development, Medical Diagnostics, Personalized Medicine, Predictive Medicine, Protein Chemistry, Chip Design, Molecular Biology, Material Science, Biophysics, Optical Engineering, Microfluidics, Bioinformatics, Software Engineering

Services & Products

Iterative Mapping Technology
Voyager Platform
Proteome Analysis
Early Access Program for Proteomics

Target Customers

Biotechnology Researchers Pharmaceutical Companies Academic Institutions Biomedical Researchers

Funding Rounds & Investors (3)

View All
Funding Stage Amount Investors Lead Investors Date
Post IPO Equity $200.00M 10
Madrona Casdin Capital RA Capital Management
Madrona, Casdin Capital +8
10 Jun 2021
Series B $76.00M -
21 May 2020
Series A $27.20M -
18 May 2018

Nautilus Biotechnology Alternatives & Competitors

View All Alternatives
Nautilus Biotechnology vs
DNA Script
DNA Script France

Transforming how molecular biology translates to human health, personalized medicine and synthetic b...

Series C
128 employees
Biotechnology, Health Care
Compare Nautilus Biotechnology vs DNA Script
Nautilus Biotechnology vs
FullDNA
FullDNA Germany

Preventing Illness before it happens translates into better care

6 employees
Analytics, Biotechnology
Compare Nautilus Biotechnology vs FullDNA
Nautilus Biotechnology vs
Magnet Biomedicine
Magnet Biomedicine United States

Revolutionizing Human Medicine with Molecular Glues

Series A
42 employees
Biotechnology, Pharmaceutical
View all alternatives

FAQ About Nautilus Biotechnology

Delivering on the Promise of the Human Proteome
Nautilus Biotechnology was founded in 2016.
Nautilus Biotechnology is headquartered in San Carlos, United States.
Nautilus Biotechnology operates in Biotechnology, Health Care, Life Sciences and Pharmaceutical. Its work centres on Proteomics, Therapeutic Development, Medical Diagnostics and Personalized Medicine. Its customers include Biotechnology Researchers, Pharmaceutical Companies and Academic Institutions.
Nautilus Biotechnology has a Platform, B2B and SaaS business model. Its revenue comes from Subscription, Usage Based and Product Sales.
Nautilus Biotechnology has approximately 148 employees.
Nautilus Biotechnology has completed 3 funding rounds, raising a total of $303.20M. The latest funding stage is Post-IPO Equity.
Nautilus Biotechnology offers: Iterative Mapping Technology, Voyager Platform, Proteome Analysis, Early Access Program for Proteomics.
Top alternatives and competitors to Nautilus Biotechnology include DNA Script, FullDNA, Magnet Biomedicine, Relay Therapeutics, HAWK Biosystems. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Nautilus Biotechnology and DNA Script are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Nautilus Biotechnology, https://bouncewatch.com/company/nautilus-biotechnology, updated 29 June 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout